News | September 20, 2013

New York Proton Consortium Expands Access To Proton Therapy Through Agreement With Procure Proton Therapy Center In New Jersey

The New York Proton Center (NYPC), a consortium of five leading hospitals in New York City, including Continuum Health Partners, Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, the Mount Sinai Medical Center, and New York University Langone Medical Center, announced an agreement with ProCure Proton Therapy Center in Somerset, N.J., CentraState Health Care System, Princeton Radiation Oncology  and management services for NYPC being provided by 21st Century Oncology, a national provider of advanced radiation oncology services. This agreement will give the consortium’s patients access to a state-of-the-art proton treatment center in Somerset, N.J., one of only twelve such centers in the nation and the only center in the New York and New Jersey region. Proton therapy is a unique form of precision radiation that directly attacks tumors while minimizing potentially damaging radiation to surrounding healthy tissues and organs.

The NYPC consortium noted in a brief statement that they are "deeply committed to providing the highest standard of care to cancer patients, which includes access to proton therapy. For certain patients, especially those with solid tumors surrounded by sensitive tissue and vital organs, proton therapy is often the treatment of choice."   

Studies have shown proton therapy to be effective in treating many types of tumors, including pediatric cancers and selected tumors of the head and neck, brain, spinalcord, breast, gastrointestinal system, lung and prostate.

Unlike traditional X-ray beams that deposit a dose of radiation all the way through the patient’s body, proton beams stop abruptly and do not deliver radiation dose beyond the tumor.  In many cases, this unique property of protons allows physicians to concentrate radiation within the tumor while reducing the dose to surrounding tissues with greater precision than can be achieved with conventional radiation beams, thereby reducing the risk of side effects and improving the patient’s quality of life.  

Recognizing these benefits of proton therapy for patients with specific tumor types, NYPC’s agreement with the ProCure Proton Therapy Center allows this therapy to be conveniently accessible for their patients. Under the agreement, patients receiving care at NYPC hospitals who need proton therapy will continue to have their treatments provided by their physicians who will now have treatment privileges at the Proton Center.

“It has always been the Mission of ProCure and our affiliate CentraState Healthcare System to make proton therapy available to as many patients as possible,” said Oren Cahlon, M.D., of Princeton Radiation Oncology, medical director of the ProCure Proton Therapy Center in Somerset, N.J. “Our agreement with NYPC allows us to share our access to proton therapy and takes us one step closer to fulfilling our mission.”

The ProCure Proton Therapy Center in Somerset, N.J., in affiliation with CentraState Healthcare System and Princeton Radiation Oncology, opened in March 2012.

For more information: www.procure.com

Related Content

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
IBA Announces First Patient Treated with Proteus PLUS in The Netherlands
News | Proton Therapy | January 25, 2018
January 25, 2018 –  IBA (Ion Beam Applications SA) has announced that the University Medical Center Groningen (UMCG)
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
Overlay Init